Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27392220.
- Also identified by DOI 10.1016/j.stem.2016.06.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Leukemia stem cells (LSCs) are resistant to current therapies used to treat chronic myeloid leukemia (CML). Abraham et al. (2016) have identified a molecular network critical for CML LSC survival and propose that simultaneously targeting two of their major transcriptional regulators, p53 and c-Myc, may facilitate their eradication.
Medical subject headings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Neoplastic Stem Cells